• Je něco špatně v tomto záznamu ?

PML and TRF2 protein expression in hereditary and sporadic colon cancer

P Plevova, J Bouchal, M Fiuraskova, M Papezova, A Krepelova, R Curik, L Foretova, M Navratilova, J Zapletalova, T Posolda, Z Kolar

. 2007 ; 54 (4) : 269-277.

Jazyk angličtina Země Slovensko

Perzistentní odkaz   https://www.medvik.cz/link/bmc10015036

The PML (promyelocytic leukemia) protein is concentrated in the PML nuclear bodies. In human cell lines and tumors maintaining their telomeres by alternative lengthening (ALT), the PML protein is colocalized with TRF2 and several other proteins in the so called ALT-associated PML bodies. The aim of this study was to determine if there is any difference in PML protein expression between tumors with stable microsatellites (MSS) and those with high-frequency microsatellite instability (MSI-H), if PML protein expression might be a prognostic factor and if MSI-H tumors more frequently use alternative lengthening of telomeres measured by the presence of ALT-associated PML bodies. Eighty colorectal cancer samples (32 MSI-H and 48 MSS) and 8 human tumor cell lines (Saos-2, U2OS, DU145, LNCaP, U87, HeLa, MCF7 and T98G) were included into the study. Double-colour immunofluorescence staining was used. Downregulation of PML protein expression was found in 7 of 32 (22%) MSI-H and 11 of 48 (23%) MSS tumors (p=0.520). There was no correlation between PML expression and age, histological typing, localization of the tumor in colon, TNM classification, disease-free and overall survival. The Saos-2 and U2OS (ALT using cell lines) and the MCF7 (active telomerase) cell line were characterized by the presence of ALT-associated PML bodies; no such bodies were detected in the DU145, LNCaP, U87, HeLa and T98G cell lines (active telomerase); accumulation of TRF2 was absent or much weaker in these cell lines compared to Saos-2 or U2OS. Accumulation of the TRF2 protein was detected in 16 of 80 (20%) tumors and PML and TRF2 colocalization in 2 MSI-H tumors (6%). In conclusion, the PML protein was downregulated in approximately 20% of tumors; there was no difference between MSS and MSI-H tumors. PML protein expression does not seem to be a prognostic factor.

000      
04457naa 2200697 a 4500
001      
bmc10015036
003      
CZ-PrNML
005      
20111210175735.0
008      
100623s2007 xo e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xo
100    1_
$a Plevová, Pavlína $7 xx0044813
245    10
$a PML and TRF2 protein expression in hereditary and sporadic colon cancer / $c P Plevova, J Bouchal, M Fiuraskova, M Papezova, A Krepelova, R Curik, L Foretova, M Navratilova, J Zapletalova, T Posolda, Z Kolar
314    __
$a Institute of Pathology and Laboratory of Molecular Pathology, Medical Faculty of the Palacky University, Olomouc, Czech Republic pavlina.plevova@volny.cz
520    9_
$a The PML (promyelocytic leukemia) protein is concentrated in the PML nuclear bodies. In human cell lines and tumors maintaining their telomeres by alternative lengthening (ALT), the PML protein is colocalized with TRF2 and several other proteins in the so called ALT-associated PML bodies. The aim of this study was to determine if there is any difference in PML protein expression between tumors with stable microsatellites (MSS) and those with high-frequency microsatellite instability (MSI-H), if PML protein expression might be a prognostic factor and if MSI-H tumors more frequently use alternative lengthening of telomeres measured by the presence of ALT-associated PML bodies. Eighty colorectal cancer samples (32 MSI-H and 48 MSS) and 8 human tumor cell lines (Saos-2, U2OS, DU145, LNCaP, U87, HeLa, MCF7 and T98G) were included into the study. Double-colour immunofluorescence staining was used. Downregulation of PML protein expression was found in 7 of 32 (22%) MSI-H and 11 of 48 (23%) MSS tumors (p=0.520). There was no correlation between PML expression and age, histological typing, localization of the tumor in colon, TNM classification, disease-free and overall survival. The Saos-2 and U2OS (ALT using cell lines) and the MCF7 (active telomerase) cell line were characterized by the presence of ALT-associated PML bodies; no such bodies were detected in the DU145, LNCaP, U87, HeLa and T98G cell lines (active telomerase); accumulation of TRF2 was absent or much weaker in these cell lines compared to Saos-2 or U2OS. Accumulation of the TRF2 protein was detected in 16 of 80 (20%) tumors and PML and TRF2 colocalization in 2 MSI-H tumors (6%). In conclusion, the PML protein was downregulated in approximately 20% of tumors; there was no difference between MSS and MSI-H tumors. PML protein expression does not seem to be a prognostic factor.
650    _2
$a adaptorové proteiny signální transdukční $x genetika $7 D048868
650    _2
$a mucinózní adenokarcinom $x genetika $x metabolismus $x patologie $7 D002288
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a kolorektální nádory $x genetika $x metabolismus $x patologie $7 D015179
650    _2
$a DNA nádorová $7 D004273
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mikrosatelitní nestabilita $7 D053842
650    _2
$a mikrosatelitní repetice $7 D018895
650    _2
$a lidé středního věku $7 D008875
650    _2
$a homolog 2 proteinu MutS $x genetika $7 D051718
650    _2
$a nádorové proteiny $x metabolismus $7 D009363
650    _2
$a nádory $x genetika $x metabolismus $x patologie $7 D009369
650    _2
$a jaderné proteiny $x genetika $x metabolismus $7 D009687
650    _2
$a polymerázová řetězová reakce $7 D016133
650    _2
$a telomerasa $x metabolismus $7 D019098
650    _2
$a protein TRF2 $x metabolismus $7 D035341
650    _2
$a transkripční faktory $x metabolismus $7 D014157
650    _2
$a nádorové buňky kultivované $7 D014407
650    _2
$a nádorové supresorové proteiny $x metabolismus $7 D025521
650    _2
$a telomery $x fyziologie $7 D016615
650    _2
$a financování organizované $7 D005381
700    1_
$a Bouchal, Jan, $d 1973- $7 xx0034399
700    1_
$a Bezděková, Michala $7 xx0100689
700    1_
$a Sekowská, Martina, $d 1975- $7 xx0090137
700    1_
$a Křepelová, Anna, $d 1955- $7 ja20020046544
700    1_
$a Čuřík, Romuald $7 xx0100572
700    1_
$a Foretová, Lenka, $d 1957- $7 nlk20000084855
700    1_
$a Navrátilová, Marie $7 xx0079497
700    1_
$a Zapletalová, Jana $7 xx0111614
700    1_
$a Posolda, Tomáš, $d 1949- $7 xx0119498
700    1_
$a Kolář, Zdeněk, $d 1953- $7 jn20000710256
773    0_
$t Neoplasma $w MED00003470 $g Roč. 54, č. 4 (2007), s. 269-277 $x 0028-2685
910    __
$a ABA008 $b A 1194 $y 8
990    __
$a 20100630105514 $b ABA008
991    __
$a 20100630105514 $b ABA008
999    __
$a ok $b bmc $g 750904 $s 614582
BAS    __
$a 3
BMC    __
$a 2007 $b 54 $c 4 $d 269-277 $i 0028-2685 $m Neoplasma $n Neoplasma $x MED00003470
LZP    __
$a 2010-B1/mkme

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...